Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim [Yahoo! Finance]
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Yahoo! Finance
Why the FDA Review Extension Matters for Savara Stock Savara (SVRA) shares are reacting to news that the FDA has extended the Priority Review of its molgramostim biologics license application for autoimmune pulmonary alveolar proteinosis by three months, shifting the target action date to November 22, 2026. See our latest analysis for Savara. The FDA extension has arrived after a mixed stretch for the share price, with a 1 day share price return of 3.64% following recent weakness. At the same time, the 1 year total shareholder return of 61.01% and 3 year total shareholder return of about 2.7x suggest longer term momentum has been strong even as shorter term sentiment has faded. If this kind of regulatory driven move has your attention, it can be helpful to widen the lens and see what else is on the move via 33 healthcare AI stocks With the shares around US$5.12, a market value of about US$1.3b, strong multi year returns and a value score of 1, the question is simple: is the
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara (SVRA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $11.00 price target on the stock.MarketBeat
- Savara (SVRA) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Savara Announces New Employment Inducement GrantBusiness Wire
- Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Business Wire
- Savara To Present New Data at the American Thoracic Society (ATS) 2026 International ConferenceBusiness Wire
SVRA
Earnings
- 11/12/25 - Miss
SVRA
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- SVRA's page on the SEC website